Loading...
Market
Outcome of Biogen's biotech acquisition attempts by end of 2025
2
Chris Viehbacher•JPMorgan Healthcare Conference•San Francisco•Viehbacher•Biogen•Sage Therapeutics•Zurzuvae•Sage
Resolution / Starting Odds
Successful acquisition of Sage Therapeutics • 25%
Successful acquisition of another biotech • 25%
No acquisitions completed • 25%
Multiple acquisitions completed • 25%
Official press releases from Biogen, major financial news outlets
Story
Biogen CEO Confirms Intent to Acquire Biotechs, Including $469 Million Offer for Sage Therapeutics
Jan 12, 2025, 04:01 PM
Biogen Inc. is actively seeking to expand its portfolio through acquisitions in the biotech sector, as confirmed by CEO Chris Viehbacher at the JPMorgan Healthcare Conference in San Francisco. Viehbacher expressed Biogen's intent to engage in deals, though he did not specify the size of these potential acquisitions. This comes after Biogen's recent $469 million offer to acquire Sage Therapeutics, its partner in marketing Zurzuvae, a pill for postpartum depression. The offer, which is less than Sage's current cash reserves, is unlikely to be accepted due to Sage's recent clinical failures and stock price decline. Biogen's strategy is to target biotechs with drugs in mid- and late-stage clinical development to augment its growth.
View original story
Similar markets
No further acquisitions • 25%
Stoke Therapeutics • 25%
Another named biotech company • 25%
Multiple companies • 25%
Acquisition completed at a different price • 25%
Acquisition rejected • 25%
Acquisition not completed • 25%
Acquisition completed at proposed price • 25%
Offer revised • 25%
Other outcome • 25%
Acquisition completed • 25%
Offer rejected • 25%
Other • 25%
Johnson & Johnson • 25%
GSK • 25%
Eli Lilly • 25%
Eli Lilly • 25%
Pfizer • 25%
GSK • 25%
Other • 25%
Gilead Sciences • 25%
Biogen • 25%
Other Biopharma Companies • 25%
Vertex Pharmaceuticals • 25%
Proceed with acquisition • 25%
Increase offer • 25%
Other actions • 25%
Withdraw offer • 25%
Decreases by more than 10% • 25%
Increases by more than 50% • 25%
Increases by 30-50% • 25%
Remains stable (±10%) • 25%
Acquisition Abandoned • 25%
Other Outcomes • 25%
Acquisition Delayed • 25%
Acquisition Completed • 25%